News | Breast Imaging | June 28, 2017

Laser Imaging "Bowl" to Give Instant Test for Breast Cancer

European scientists developing photoacoustic imaging system to increase patient comfort and shorten the diagnostic process

Laser Imaging "Bowl" to Give Instant Test for Breast Cancer

June 28, 2017 — In a bid to make the world's first while-you-wait test for breast cancer, European scientists are developing a comfortable hemispherical bowl lined with laser sources and ultrasound detectors with the potential to reduce the stages in spotting the disease into a single appointment.

Current breast cancer diagnosis can be distressing and painful over a number of weeks. Multiple stages can involve visiting a general practitioner, being sent to a specialist for an X-ray mammogram, having an ultrasound, before undergoing a needle, a punch or a vacuum assisted biopsy, as well as placing one breast at a time between two metal plates in a painful clamp.

However, a new imaging system being developed by scientists at the University of Twente in the Netherlands intends to remove the discomfort and uncertainty involved in a diagnosis.

The device employs both light and sound together in a technique called photoacoustics, combining lasers and photonics with ultrasound detection.

The size of a hospital bed, a patient lies face down placing their breast snugly into the ‘reader’, a hemispherical ‘bowl’ lined with up to a hundred optical fibers and several ultrasound detectors.

Multiple images of a suspect breast and tumor are then acquired from dozens of different angles before assembling the multiple shots into a single 3-D image. 

The ‘PAMMOTH’ (Photoacoustic Ultrasound Mammoscopy for evaluating screening-detected abnormalities in the breast), hopes to lead the researchers into photoacoustic, real-time 3-D imaging of suspicious lesions.

Project coordinator Srirang Manohar explained, “We are creating an imaging device that we hope will reduce all of the stages involved in spotting breast cancer into one convenient appointment in order to reduce time, uncertainty and the number of unnecessary biopsies. We intend to make breast cancer diagnosis a one-stop-shop, while you wait.”

It works by sending short pulses of light into the breast towards the suspected lesion. Some of the delivered energy will be absorbed in the tissue and converted into heat, leading to transient thermoelastic expansion, or a mechanical ‘push’ signal from the suspected tumor.

Ultrasound detectors on the surface of the breast, from the hemispherical reader bowl where the breast is placed, can then detect and measure these push signals before analyzing them on-site. Here the imager can look into the hemoglobin (the oxygen-carrying protein in the blood) activity within the suspected tumor.

Since tumors consume oxygen at high rates to survive, lower oxygenation levels around a suspect lesion could tell a physician that a suspect lump is more likely to be a malignant growth than not.

The imager employs a multi-wavelength illumination in the near-infrared wavelength region to extract information about blood oxygenation, using PAMMOTH’s own image reconstruction methods.

As part of the PAMMOTH team, researchers at University College London (UCL) are working on the mathematics, the image reconstruction and the analysis of the signals to determine how aggressive a tumor could be.

By gathering key information about the hemoglobin and oxygenation levels to and from the suspected tumor, the user could diagnose how likely it would be for the tumor to spread or whether it was simply benign.

“An aggressive tumor has a high metabolism and consumes oxygen more rapidly than normal tissue or a benign lesion. Our instrument and the mathematical approaches we are developing could allow us to check the oxygen saturation rate accurately,” said Manohar. “If a patient’s oxygen saturation rate was found to be considerably lower than surrounding tissue then we could pinpoint where an aggressive tumor could be, and radiologists could understand how the tumor is likely to behave.”

Current techniques to diagnose breast cancer such as X-ray mammography, ultrasound or magnetic resonance imaging (MRI) scans can sometimes fail to spot a tumor from healthy tissue or a benign abnormality, resulting in tumors that are missed and unnecessary biopsies being carried out.

Unnecessary biopsies and risks of false positives in breast cancer diagnosis are hotly contested topics among medical experts. As well as the untold stress and discomfort experienced by women all over the world by unnecessary treatments, inefficient diagnoses have an extremely worrying cost implication.

Every year in the United States alone, $4 billion is spent on false-positive mammograms and breast cancer over diagnosis among women ages 40-59, according to research published in Health Affairs. A similar picture is played out across Europe with millions of Euros being spent on unnecessary mammograms.

“A prime focus of the PAMMOTH project is to develop an imager and data analysis to be able to intervene at a very early stage. We need to be able to say whether a suspect lesion is good or bad. This technique would have a substantial impact upon the money spent on unnecessary biopsies, as well as to remove the trauma involved in a diagnosis for women around the world,” said Manohar.

The PAMMOTH team hopes to have a prototype ready for 2020 ready for completion in 2021.

Coordinated in the Netherlands at the University of Twente, the PAMMOTH project received a grant of €4,352,007.50 from Horizon 2020 via the Photonics Public Private Partnership.

For more information: www.photonics21.org

Related Content

Mary C. Mahoney, M.D.

Mary C. Mahoney, M.D.

News | RSNA | December 01, 2020
December 1, 2020 — At the Virtual RSNA 2020 conference, it was a
Researchers developed a deep learning model that identifies imaging biomarkers to predict a patient’s risk for developing breast cancer

A deep learning model was developed that combined imaging and traditional risk factors.

News | Mammography | November 30, 2020
November 30, 2020 — Researchers at Massachusetts General Hospi...
ProFound AI for DBT offers superior clinical performance when compared to other commercially available breast AI systems
News | Breast Imaging | November 24, 2020
November 24, 2020 — iCAD reported that over 1,000 licenses have been sold as part of...
Densitas Inc., a global provider of A.I. technologies for digital mammography and breast screening, announced its partnership with Mammography Educators to offer the first artificial intelligence powered telehealth technologist training platform to support business continuity in mammography facilities.
News | Mammography | November 20, 2020
November 20, 2020 — Densitas Inc., a global provider of A.I.
Radiologists around the world will have access to a first-of-its-kind online breast density training tool designed to improve radiologists' ability to correctly identify women's breast density categories to comply with the Breast Imaging-Reporting and Data System (BI-RADS), thanks to a collaboration between DetectED-X and Volpara Health. 
News | Breast Density | November 19, 2020
November 19, 2020 — Radiologists around the world will have access to a first-of-its-kind online...
Reduces the complexity of reporting for screening and diagnostic MRI eams to deliver time-saving and patient safety benefits
News | MRI Breast | November 18, 2020
November 18, 2020 — ...
An interview with Professor Christiane Kuhl, M.D., director of radiology, University Hospital Aachen, Germany, on the effects on breast imaging in the COVID-19 era

Getty Images

Feature | Breast Imaging | November 12, 2020 | By Dave Fornell
The pandemic forced many elective procedures, including most areas of...
Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single

Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single-slice DBT image in craniocaudal view. C, Magnification of the lesion depicted in B. D, Image from SM in mediolateral oblique view. E, Single-slice DBT image in mediolateral oblique view. F, Magnification of the lesion depicted in E. Images courtesy of Radiological Society of North America

News | Breast Imaging | November 11, 2020
November 11, 2020 — ...